Arcus Biosciences, Inc. (RCUS) Operating margin 2017–2025
Arcus Biosciences, Inc. (RCUS) operating margin by fiscal year — reported operating income divided by reported revenue.
-1169.7%FY2025 · since FY2017: -3782.1% → -1169.7%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1169.7% | -522.6 pp |
| FY2024 | -647.1% | +271.9 pp |
| FY2023 | -918.9% | -182.1 pp |
| FY2022 | -736.8% | -750.9 pp |
| FY2021 | 14.1% | +173.1 pp |
| FY2020 | -159.0% | +432.4 pp |
| FY2019 | -591.4% | +65.4 pp |
| FY2018 | -656.8% | +3125.3 pp |
| FY2017 | -3782.1% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More RCUS financial trends
RCUS RevenueRCUS Net incomeRCUS Net marginRCUS Gross profitRCUS Gross marginRCUS Operating incomeRCUS Operating cash flowRCUS Free cash flowRCUS Capital expendituresRCUS Return on equityRCUS Stock buybacksRCUS Dividends paidRCUS Total assetsRCUS Total liabilitiesRCUS Shareholders’ equityRCUS overview →